GlassScriptPhysician profile
Gary Ronald Monash
NPI 1891771846
$10,520.92
in general payments reported to CMS, 2019-2025
35 companies · $2,024 in 2025
The $2,024 reported for 2025 was more than what 79% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $995 · 2020: $613 · 2021: $1,550 · 2022: $1,905 · 2023: $1,724 · 2024: $1,710 · 2025: $2,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,357 · Education: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,357.26 |
| Education | $100.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,801.34 | 2019-2025 | |
| Janssen Biotech, INC. | $1,211.24 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Celgene Corporation | $628.69 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $599.94 | 2021-2025 | Livdelzi |
| Takeda Pharmaceuticals U.S.A., INC. | $548.13 | 2019-2025 | Entyvio, Eohilia |
| Ferring Pharmaceuticals INC. | $504.55 | 2019-2025 | Rebyota |
| Aimmune Therapeutics, INC. | $455.94 | 2024-2025 | Zenpep |
| Janssen Scientific Affairs, LLC | $258.91 | 2019-2022 | |
| Intercept Pharmaceuticals, INC. | $245.78 | 2019-2025 | Ocaliva |
| Pfizer INC. | $239.90 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $226.59 | 2020-2024 | Linzess |
| Madrigal Pharmaceuticals | $191.26 | 2024-2025 | Rezdiffra, Resmetirom |
| Phathom Pharmaceuticals, INC. | $176.57 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $176.46 | 2019-2023 | Trulance |
| Nestle Healthcare Nutrition INC. | $134.80 | 2021-2023 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2021 | |
| Braintree Laboratories, INC. | $110.47 | 2019-2022 | |
| Ucb, INC. | $110.27 | 2019-2020 | |
| Boston Scientific Corporation | $105.37 | 2022 | |
| Genzyme Corporation | $90.54 | 2022-2023 | |
| Qol Medical, LLC | $87.09 | 2019 | |
| Lilly USA, LLC | $61.01 | 2024-2025 | Omvoh |
| Ardelyx, INC. | $57.82 | 2022-2024 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $57.44 | 2022-2025 | Dupixent |
| Daiichi Sankyo INC. | $51.92 | 2019-2021 | |
| Medtronic, INC. | $46.02 | 2022-2024 | Gi Genius |
| Allergan, INC. | $41.36 | 2019 | |
| Alfasigma USA, INC. | $40.73 | 2020 | |
| Evoke Pharma, INC. | $29.23 | 2025 | |
| Novo Nordisk INC | $25.49 | 2025 | Wegovy |
| Biocompatibles, INC. | $21.70 | 2019 | |
| Amgen INC. | $18.31 | 2023 | Amjevita, Avsola |
| Redhill Biopharma INC. | $17.42 | 2020 | |
| Capsovision, INC. | $13.15 | 2023 | Capsocam Plus |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Monash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.